Healthy Stool Volunteer Donors for Fecal Microbiota Transplantation Trials

NCT ID: NCT06478823

Last Updated: 2024-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-08

Study Completion Date

2030-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials. The collection and validation of these stool donations as part of the trials is complex and not very efficient. It therefore seems essential to identify the limiting factors and the characteristics of Healthy Volunteer Donors to optimize the number of valid stool donations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

If the ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials, the selection, inclusion of Healthy Volunteer Donors (HVD), then the collection and validation of these stool donations is complex and not very effective. New recommendations related to COVID-19 make this process even more complex. It therefore seems essential to identify the limiting factors and the characteristics of HVD to optimize the number of valid stool donations.

Healthy voluntary donors of stools for the preparation of TMF (Healthy Volunteer Donors, -TMF) for trials to evaluate its effectiveness in various pathologies will be selected, included and followed in a common protocol (ANSM agreement obtained) in order to facilitate this entire process and pool resources. This will allow us to describe the clinical characteristics and lifestyle habits of Healthy Volunteer Donors associated with the validity of stool donations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastro-Intestinal Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers for stool donation

Group Type EXPERIMENTAL

Stools donation

Intervention Type OTHER

Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.

Donors will be followed from their selection until 6 months after their last valid stool donation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stools donation

Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.

Donors will be followed from their selection until 6 months after their last valid stool donation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Age ≥ 18 years and \< 50 years

* 17 kg/m² \< body mass index \< 30 kg/m²
* Regular bowel movement defined as at least 1 stool every other day and maximum 2 stools per day
* Subject with health insurance (AME excepted)
* Informed written consent


1. Infectious risk :

\- Known HIV, HBV, HCV, HTLV infection

\- Residence of more than 2 years in the intertropics zone within the previous 5 years

\- Hospitalization abroad for more than 24 hours in the last 12 months (including a member of the healthy volunteers donor's entourage)

\- Risk factors for Creutzfeldt-Jakob disease (history: treatment with extractive growth hormone, a family case of transmissible spongiform subacute encephalopathy, surgery with opening of the dura or neurosurgery or invasive brain exploration before 1 January 1995, stay in United Kingdom for a duration greater than 1 year cumulatively between 1980 and 1996 or the presence of neurological or neuropsychiatric scalable recent clinical signs)
* Previous history of typhoid fever, tuberculosis and malaria
* Past or current injection drug user or regular use of other drug
2. Gastrointestinal disease:

\- Personal or 1st degree family history of: inflammatory bowel disease or celiac disease

\- Personal history of irritable bowel syndrome, idiopathic chronic constipation or chronic diarrhea

\- Previous history of gastrointestinal neoplasia or polyps

\- Family history of 1st degree gastrointestinal neoplasia or polyps before age 60
3. 1st degree family history of one of the following autoimmune or inflammatory disease : inflammatory arthritis, psoriasis, multiple sclerosis, type I diabetes, spondylitis, lupus and Basedow disease

\- If family history unknown in the first degree, the donor is not eligible
4. Previous history of :

* Subject prone to hemorrhoids (at least 1 event within the previous 1 year)
* Subject with an active chronic illness (except active chronic mild allergic disease o (example: allergic rhinitis, chronic eczema…))

* Diagnosis of Gilbert's syndrome done by screening is not a chronic disease. The healthy volunteer donor will therefore remain eligible.
* Serious allergy requiring hospitalization within the previous 12 months
* Curative long-term treatment
* Severe allergy requiring hospitalization in the last 12 months
* Allogeneic human or animal tissue or organ transplant
* 5- Factors that may affect the composition of the intestinal microbiota:
* Special Diet (example: gluten-free...)
* Lactose-free, vegetarian and vegan diets are permitted.
* Pregnancy or breastfeeding
* Taking immunosuppressants (eg calcineurin inhibitors, corticosteroids, biological agents, etc.)
* Antineoplastic chemotherapy


1. Infectious risk :

* Unprotected sexual intercourse with a new partner in the previous 4 months and/or sexual intercourse with several different persons within the previous 4 months
* sexual partner who has had more than 1 partner within the previous 4 months and/or
* sexual transmitted infection within the previous 4 months (healthy volunteer donor himself or sexual partner)
* Sexual relationship in exchange for money or drugs in the last 12 months. (healthy volunteer donor himself or sexual partner)
* Sexual relationship with a partner with positive serology for HIV, viral hepatitis B or C, in the last 6 months.
* Sexual relationship with a partner who has used intravenous drugs, doping substances
* Hospitalization abroad for more than 24 hours in the last 12 months (healthy volunteer or entourage)
* Travelling within the previous 3 months except : Germany, Austria, Belgium, Spain, Finland, Ireland, Italia, Luxembourg, Netherland, Portugal, Greece, Slovenia, Cyprus, Malta, Slovakia, Estonia , Bulgaria, Croatia , Hungary, Latvia , Lithuania, Poland , Romania, Czech Republic, the United Kingdom, Denmark, Norway, Sweden, Switzerland, USA or Canada.
* Blood transfusion, piercing (including earrings) or tattoo within the previous 4 months
* Surgery (all types) or hospitalization within the previous 4 months
* Person living under the same roof with an infectious or contagious disease (i.e who have been hospitalized) within the previous 4 months
* Blood exposure accident (for wound, pricking or projection ...) within the previous 4 months
* Dental care within the previous 7 days
* Gastroenteritis within the previous 3 months (defined by acute onset of diarrhea (\> 3 soft or liquid stools per day) and duration \< one week)
* Episode of infection or skin infection/lesion within the previous 15 days 2-Risk linked to Covid-19
* Confirmed infection in the previous 28 days (after symptoms have ceased)
* Clinical signs of suspected infection (chill, cough, fever, dyspnea, myalgia, asthenia, malaise, pharyngeal pain, anosmia , ageusia, rhinorrhea, chest pain, headache, diarrhea) in the previous 28 days (after the end of symptoms)
* Having been in risky contact (according to the definition of Santé Publique France with a person whose infection is confirmed or suspected: "14 days after the last risky contact: if the recommended screening tests in the event of risky contact between D15-D28 are negative "In the 28 days preceding inclusion in the absence of a screening test. Healthcare professionals using recommended protective measures with COVID patients are not considered high-risk contacts 3- Monkeypox risk
* Confirmed or suspected infection within the previous 42 days ( after beginning of symptoms)
* Risky contact with a person with confirmed or suspected infection within the previous 21 days (from the date of last contact)
* Person who received the vaccine Imvanex within the previous 28 days ( after the last injection).

4- vaccination in the previous 15 days

5- Factors that may affect the composition of the intestinal microbiota:
* Taking antibiotic or antifungal (oral) in the previous 3 months before donation
* Taking non-steroidal anti-inflammatory drugs (oral) in the previous month before donation
* Taking corticosteroids (oral) in the previous 4 weeks before donation. Corticosteroids allowed if taken more than 4 weeks before donation. and not for an autoimmune or inflammatory disease.
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CRB-SAT BARM APHP.SU

UNKNOWN

Sponsor Role collaborator

CRSA UMRS 938

UNKNOWN

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mélissa Montil

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

LRIPH CRC-Est SAT

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mélissa Montil, Praticien attaché

Role: CONTACT

00 33 1 71 97 08 10

Harry SOKOL

Role: CONTACT

00 33 1 49 28 31 62

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Melissa MONTIL

Role: primary

Harry SOKOL

Role: backup

00 33 1 49 28 31 62

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A01401-42

Identifier Type: OTHER

Identifier Source: secondary_id

APHP220606

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Freeze-dried, Capsulized FMT for RCDI
NCT02399618 UNKNOWN PHASE1
Stool Transplant to Control Treatment-related Diarrhea
NCT04883762 ACTIVE_NOT_RECRUITING PHASE1